OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Daniel J. Gerritzen Sells 5,310 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $132,006.60. Following the completion of the sale, the general counsel now owns 110,767 shares of the company’s stock, valued at $2,753,667.62. This trade represents a 4.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

OrthoPediatrics Stock Performance

Shares of KIDS traded up $0.46 during mid-day trading on Tuesday, reaching $25.42. The company’s stock had a trading volume of 138,044 shares, compared to its average volume of 162,840. OrthoPediatrics Corp. has a 1-year low of $21.02 and a 1-year high of $35.99. The stock has a market cap of $617.38 million, a P/E ratio of -20.67 and a beta of 1.22. The business has a 50-day simple moving average of $24.74 and a two-hundred day simple moving average of $25.62. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The company had revenue of $52.67 million during the quarter, compared to analysts’ expectations of $51.16 million. During the same period last year, the firm posted ($0.23) earnings per share. As a group, equities research analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on KIDS shares. Truist Financial decreased their price objective on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Needham & Company LLC restated a “buy” rating and issued a $42.00 price target on shares of OrthoPediatrics in a research note on Wednesday, March 5th. Finally, Stifel Nicolaus decreased their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, March 5th.

Institutional Trading of OrthoPediatrics

Several hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in OrthoPediatrics by 20.2% during the 4th quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company’s stock worth $24,601,000 after purchasing an additional 178,078 shares during the last quarter. Wasatch Advisors LP lifted its holdings in OrthoPediatrics by 47.2% during the 4th quarter. Wasatch Advisors LP now owns 696,318 shares of the company’s stock worth $16,141,000 after purchasing an additional 223,217 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in OrthoPediatrics by 29.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock worth $15,576,000 after purchasing an additional 152,681 shares during the last quarter. AWM Investment Company Inc. lifted its holdings in OrthoPediatrics by 14.8% during the 4th quarter. AWM Investment Company Inc. now owns 516,794 shares of the company’s stock worth $11,979,000 after purchasing an additional 66,779 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in OrthoPediatrics during the 4th quarter worth approximately $9,798,000. 69.05% of the stock is owned by institutional investors and hedge funds.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.